Herb-Drug Interactions: Challenges and Opportunities for Improved Predictions by Brantley, S. J. et al.
1521-009X/42/3/301–317$25.00 http://dx.doi.org/10.1124/dmd.113.055236
DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 42:301–317, March 2014
Copyright ª 2014 by The American Society for Pharmacology and Experimental Therapeutics
Perspective
Herb–Drug Interactions: Challenges and Opportunities for
Improved Predictions
Scott J. Brantley, Aneesh A. Argikar, Yvonne S. Lin, Swati Nagar, and Mary F. Paine
Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina,
Chapel Hill, North Carolina (S.J.B.); Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia,
Pennsylvania (A.A.A., S.N.); Department of Pharmaceutics, University of Washington, Seattle, Washington (Y.S.L.); and College of
Pharmacy, Washington State University, Spokane, Washington (M.F.P.)
Received October 4, 2013; accepted December 11, 2013
ABSTRACT
Supported by a usage history that predates written records and the
perception that “natural” ensures safety, herbal products have
increasingly been incorporated into Western health care. Con-
sumers often self-administer these products concomitantly with
conventional medications without informing their health care
provider(s). Such herb–drug combinations can produce untoward
effects when the herbal product perturbs the activity of drug
metabolizing enzymes and/or transporters. Despite increasing
recognition of these types of herb–drug interactions, a standard
system for interaction prediction and evaluation is nonexistent.
Consequently, the mechanisms underlying herb–drug interactions
remain an understudied area of pharmacotherapy. Evaluation of
herbal product interaction liability is challenging due to variabil-
ity in herbal product composition, uncertainty of the causative
constituents, and often scant knowledge of causative constituent
pharmacokinetics. These limitations are confounded further by
the varying perspectives concerning herbal product regulation.
Systematic evaluation of herbal product drug interaction liability,
as is routine for new drugs under development, necessitates iden-
tifying individual constituents from herbal products and characteriz-
ing the interaction potential of such constituents. Integration of this
information into in silico models that estimate the pharmacokinetics
of individual constituents should facilitate prospective identification
of herb–drug interactions. These concepts are highlighted with the
exemplar herbal products milk thistle and resveratrol. Implementation
of this methodology should help provide definitive information to both
consumers and clinicians about the risk of adding herbal products to
conventional pharmacotherapeutic regimens.
Introduction
Brief History of Natural Product Use for Medicinal Purposes.
Healing plants gracing Neanderthal tombs and in the personal
belongings of Ötzi the Iceman indicate that knowledge of the phar-
macologic activity of herbs and other natural products predates written
records (Tyler, 2000; Goldman, 2001). Exploitation of natural products
for both therapeutic and nefarious purposes during the Greek and
Roman empires was well documented by Hippocrates and Galen (Forte
and Raman, 2000). Perhaps the most famous early use of an herbal
product for pharmacologic activity was the execution of Socrates by
poison hemlock. By the early 19th century, the scientific method had
advanced such that promotion of natural products for healing purposes
was considered quackery (Winslow and Kroll, 1998). During the 1950s
in the United States, herbal products began to regain popularity due
to pharmaceutical tragedies, such as the use of thalidomide during
pregnancy (Brownie, 2005). The herbal product market continued to
grow in the 1960s, as consumers focused on the perceived lack of side
effects and advances in scientific knowledge about natural products
(Winslow and Kroll, 1998; Tyler, 2000). In 1974, the World Health
Organization began encouraging developing countries to supplement
modern pharmacotherapy with traditional herbal medicines to fulfill
needs unmet by conventional drugs (Winslow and Kroll, 1998). Herbal
product sales have continued to increase, reaching an estimated $5.6
billion in the United States in 2012 (Lindstrom et al., 2013).
Prevalence of Coadministration of Herbal Products with
Conventional Medications. An accurate estimate of the prevalence
of herbal product usage and coadministration with conventional
medications is difficult, because consumers of herbal products seldom
inform their health care providers (Gardiner et al., 2006). Since these
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products usually are self-administered as a means to treat or prevent
the onset of a medical condition (Winslow and Kroll, 1998), concomi-
tant intake with conventional medications can be expected (Gardiner
et al., 2006; Kennedy et al., 2008). The National Health Interview
Survey provides the most comprehensive evaluation of herbal product
usage rates in the United States, the most recent of which reported that
approximately 20% of the population acknowledges taking herbal
products (Bent, 2008). This percentage may be even greater in patients
with medical conditions such as chronic gastrointestinal disorders, in-
somnia, liver disease, chronic pain, depression, asthma, and menopause
(Gardiner et al., 2006). Of the survey responders who took an herbal
product with conventional therapy, nearly 70% neglected to inform their
health care providers (Gardiner et al., 2006; Kennedy et al., 2008).
These practices raise concerns about increased probability of an adverse
herb–drug interaction (HDI)—any alteration of the “victim” drug’s
pharmacokinetics and/or pharmacodynamics perpetrated by an herbal
product that may lead to drug-related toxicity or reduced efficacy.
Knowledge of mechanisms underlying HDIs is critical to identify and
prevent adverse interactions prospectively, as well as to modulate po-
tentially beneficial interactions. Because most reported HDIs are of
pharmacokinetic (PK) origin (Shi and Klotz, 2012), this review focuses
on PK-based HDIs.
Biochemical Mechanisms Underlying Pharmacokinetic HDIs
Inhibition of Drug Metabolizing Enzymes. Drug-mediated
inhibition of drug metabolizing enzymes is the most common and
well studied mechanism underlying PK drug–drug interactions (DDIs)
(Wienkers and Heath, 2005). Enzyme inhibition can manifest as re-
versible or irreversible loss of activity, the kinetics of which can range
from relatively straightforward (e.g., Michaelis–Menten) to complex
(atypical) and should be considered for appropriate experimental
design and data interpretation (Tracy, 2006). The proceeding concepts
are predicated on the assumption that Michaelis–Menten kinetics
apply.
Reversible Inhibition. Competitive inhibition occurs when the
“perpetrator” drug or other xenobiotic, including an herb, binds to the
active site of the enzyme, preventing the victim drug from binding (Lin
and Lu, 1998; Hollenberg, 2002) (Fig. 1). The simplest case is when two
substrates for the same enzyme are administered concomitantly, albeit the
perpetrator need not be a substrate for the enzyme to demonstrate
competitive inhibition (Kunze et al., 1991). The functional consequence is
that higher concentrations of the victim drug are needed to compete for
the binding site, thereby increasing the concentration needed for half-
maximal rate of metabolism (Km) while having no change in the maximal
rate of metabolism (Vmax) (Lin and Lu, 1998; Hollenberg, 2002). The net
result is a decrease in the intrinsic clearance (Vmax/Km or Clint) of the
victim drug. Noncompetitive inhibition occurs when the perpetrator binds
to a region of the enzyme that decreases the enzyme’s capacity to
metabolize the victim drug (Fig. 1). Since the perpetrator does not bind to
the same site on the enzyme as the victim drug, increasing victim drug
concentrations cannot compensate for the decreased activity, leaving Km
unchanged while decreasing Vmax (Lin and Lu, 1998; Hollenberg, 2002);
the net result is a decrease in Clint. Uncompetitive inhibition occurs when
the perpetrator binds to the enzyme–victim drug complex, modulating
both and Km and Vmax (Lin and Lu, 1998; Hollenberg, 2002) (Fig. 1); Clint
may or may not change. Regardless of the mode of reversible inhibition,
return to basal enzyme activity can be achieved by removing the per-
petrator from the system. Clinically, reversible inhibition, via competitive
and noncompetitive modes, manifests as an increase in the systemic
exposure of the victim drug due to a decrease in metabolic clearance and/
or increase in bioavailability.
Irreversible Inhibition. Inhibition by perpetrators that do not
associate and dissociate rapidly from the enzyme is termed time-
dependent inhibition (TDI). Mechanism-based inhibition (MBI), often
observed as TDI, is characterized by irreversible or quasi-irreversible
noncovalent binding of a reactive metabolite to the enzyme (Grimm
et al., 2009). Such binding can impede access to the active site, target
the protein for proteasomal degradation, or alkylate the heme (Silverman
and Daniel, 1995; Kalgutkar et al., 2007) (Fig. 1). Comprehensive
reviews detail the mechanisms and clinical implications of irreversible
inhibition (Venkatakrishnan et al., 2007; Grimm et al., 2009). Due to the
time-dependent nature, onset of irreversible inhibition in vivo can appear
to be delayed from initial exposure to the perpetrator (Grimm et al.,
2009). Like reversible inhibition, irreversible inhibition will manifest as
an increase in the systemic exposure of the victim drug. Unlike reversible
inhibition, the interaction can persist after removal of the perpetrator since
recovery of enzyme activity depends on de novo protein synthesis
(Grimm et al., 2009).
Inhibition of Protein-Mediated Flux. Compared with metabolism-
based interactions, mechanistic information about transporter-based
interactions is limited, although the knowledge gap is beginning to
narrow (Han, 2011). Similar to drug metabolizing enzymes, transport
proteins are susceptible to competitive and noncompetitive reversible
inhibition due to the perpetrator blocking the victim drug binding site
or causing a conformational change that decreases transport activity,
respectively (Arnaud et al., 2010; Harper and Wright, 2013). In
addition to these traditional modes of inhibition, the in vitro activity of
drug transporters can be modulated by the composition of the cell
membrane; however, the clinical consequence remains unclear
(Annaba et al., 2008; Molina et al., 2008; Kis et al., 2009; Clay and
Sharom, 2013). Inhibition of transporter activity in vivo can manifest
as increased or decreased systemic exposure and possibly altered
tissue concentrations of the victim drug. The direction of change
depends on the site of transporter expression (i.e., apical/canalicular or
basolateral/sinusoidal) and direction of flux (i.e., uptake or efflux).
Induction of Drug Metabolizing Enzymes and Transporters. In
addition to inhibition, DDIs can reflect increased enzyme or transporter
expression. Common mechanisms of induction include increased gene
transcription or stabilization of mRNA or active protein (Okey, 1990).
The predominant mechanism for enzyme and transporter induction is a
receptor-mediated increase in gene transcription due to the perpetrator
activating one or more nuclear receptors (Hewitt et al., 2007). Binding of
the perpetrator to the ligand binding domain of a nuclear receptor causes
a cascade of events leading to the activated receptor binding to the
xenobiotic response element located in the promoter region of the gene
(Fig. 1). This process leads to increased transcription and subsequent
translation of mRNA into protein (Lin and Lu, 1998). Induction of protein
function also can reflect stabilization of mRNA or protein (Novak and
Woodcroft, 2000; Raucy et al., 2004; Kato et al., 2005; Ménez et al.,
2012). Enzyme induction manifests clinically as increased clearance or
decreased bioavailability of the victim drug, leading to a decrease in
systemic exposure. Like inhibition, induction of transporters manifests as
increased or decreased circulating and/or tissue concentrations of the victim
drug depending on the site of transporter expression and direction of flux.
Challenges with Evaluating and Predicting PK HDIs
As aforementioned, both PK and pharmacodynamic (PD) mecha-
nisms underlie HDIs. PD mechanisms include common receptors or
signaling pathways between the herb and drug targeted for therapy and
any common off-target receptors or pathways. Whereas the drug
alone may not modulate an off-target mechanism significantly, it
is conceivable that a concomitant herb might exacerbate off-target
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modulation and perpetrate an unexpected adverse event. Such mech-
anisms result in the biologic action of an herbal product antagonizing,
enhancing, or synergizing that of the victim drug (Shi and Klotz,
2012). The most commonly reported PD-based HDIs involve
antithrombotic drugs, because several herbal products have anticoag-
ulant, antiplatelet, and/or fibrinolytic properties; for example, gingko
and garlic have been implicated to increase the bleeding risk of
warfarin (de Lima Toccafondo Vieira and Huang, 2012; Tsai et al.,
2013). Other widely reported PD interactions include those involving
central nervous system–active agents. For example, St. John’s wort
can elicit a manic episode or serotonin syndrome when taken with
selective serotonin-reuptake inhibitors, including sertraline, fluoxetine,
paroxetine, and nefazodone; the underlying mechanism likely involves
an additive effect of St. John’s wort on serotonin reuptake (de Lima
Toccafondo Vieira and Huang, 2012; Shi and Klotz, 2012).
As discussed earlier, the majority of potential HDIs are of PK
origin. These interactions typically involve an alteration in the victim
drug’s clearance or systemic exposure due to inhibition or induction
by the herbal product of drug metabolizing enzymes and transporters
(de Lima Toccafondo Vieira and Huang, 2012; Shi and Klotz, 2012).
The proceeding discussion focuses on common challenges when
assessing such PK-based HDIs.
Variability in Herbal Product Composition. Unlike most drug
products, herbal products frequently consist of multiple constituents that
vary in composition, both between manufacturers and between batches
from the same manufacturer. The putative bioactive constituents in herbal
products often are plant-derived secondary metabolites produced as part
of normal plant metabolism or as a reaction to environmental stress
(Rousseaux and Schachter, 2003). The relative concentration of each
pharmacologically active compound may vary widely depending on
growing conditions such as temperature and rainfall (Rousseaux and
Schachter, 2003). A simple illustration of this variability is the extreme
differences in wine quality and price between vineyards and vintages,
even when produced from the same variety of grapes (Paine and Oberlies,
2007). Strict attention should be paid to the composition of herbal prod-
ucts to ensure reproducibility within studies and to enable comparisons
between studies. At minimum, the brand name, manufacturer, lot number,
ingredients, preparation and storage directions, manufacturing process, and
origins of growth and production should be provided (Won et al., 2012).
Identification of Causative Constituents. Modulation of drug
metabolizing enzymes and transporters by herbal products can reflect
interactions with one or more herbal product constituent. The net effect
can result from additive, synergistic, or antagonistic interactions among
multiple constituents (Efferth and Koch, 2011). Accordingly, identifi-
cation of the causative constituent(s) is required to make accurate
predictions of HDIs. Some herbal products, including St. John’s wort
and milk thistle, are well characterized, and individual constituents have
been isolated in quantities sufficient for interaction screening (Obach,
2000; Weber et al., 2004; Lee et al., 2006; Graf et al., 2007; Tatsis et al.,
2007; Brantley et al., 2010, 2013). Other techniques, such as bioactivity-
guided fractionation (Kim et al., 2011a; Roth et al., 2011), can be used
to elucidate the causative constituents from herbal products.
Pharmacokinetics of Causative Constituents. As with conven-
tional DDI predictions, knowledge of the pharmacokinetics of the
perpetrator herbal product is needed to make accurate predictions of
HDIs. Herbal product constituents that undergo extensive presystemic
(first-pass) clearance via metabolism and/or efflux in the intestine and/
or liver are already marketed (e.g., milk thistle and resveratrol),
whereas traditional pharmaceutical compounds with these character-
istics typically are excluded from further development. This extensive
elimination/low bioavailability results in low circulating concentra-
tions of the parent herbal constituent. As a consequence, the systemic
concentration of the perpetrator constituent(s), if measurable, may be
a less than ideal surrogate for the concentration at the site of in-
teraction. Moreover, upon oral dosing, high presystemic exposure of
the herbal perpetrator (parent and/or metabolite) can inhibit first-pass
intestinal or hepatic extraction of the victim drug. With respect to
induction, concentrations of the victim drug (and all perpetrator con-
stituents) should be monitored upon chronic exposure to the herbal
product to detect time-dependent changes in systemic drug exposure.
Regulatory Perspectives on Herbal Products
Although regulatory agencies recommend full characterization of the
drug interaction liability of conventional pharmaceutical agents prior to
market approval, perspectives vary regarding evaluation of herbal prod-
ucts. Because herbal product usage is woven into cultural traditions, the
ability of regulatory agencies to restrict herbal pharmacotherapy and
Fig. 1. Biochemical mechanisms underlying metabolic HDIs. In
the absence of herbal constituents, drug molecules are metabolized.
Competitive inhibition by an herbal constituent prevents the drug
molecule from binding to the active site of the enzyme. Non-
competitive inhibition by an herbal constituent decreases the catalytic
activity of the drug metabolizing enzyme without interfering with the
binding of drug molecule to the enzyme active site. Uncompetitive
inhibition by an herbal constituent modulates both apparent affinity
and activity by binding to the enzyme-drug molecule complex.
Irreversible inhibition occurs when the herbal constituent mediates
enzymatic degradation. Enzyme induction occurs when herbal con-
stituents bind to nuclear receptors and activate mRNA expression and
protein synthesis.
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establish regulatory precedent is limited (Rousseaux and Schachter,
2003). Various agencies have developed different guidances for ad-
dressing the balance between market availability and safety. Cultural
and economic factors often dictate the final course of action. Regulatory
views on herbal products in the United States, the European Union, and
Canada are summarized below.
Regulation in the United States. The Food and Drug Adminis-
tration (FDA) received jurisdiction to regulate herbal products under
the Dietary Supplement Health and Education Act (1994) (DSHEA)
(Table 1). DSHEA provides the legal definition of dietary supple-
ments, including herbal products, and dictates that such supplements
be regulated as foods rather than drugs. Under this classification,
dietary supplements are presumed to be safe “within a broad range of
intake.” Herbal products marketed after passage of the DSHEA are
subject to a premarket review of safety data, whereas products sold
prior to the passage of the DSHEA are exempt (de Lima Toccafondo
Vieira and Huang, 2012). Contrary to conventional drugs, the burden
of proof is on the FDA to demonstrate that these products pose
“significant or unreasonable risk” before removal from the market
(Brownie, 2005). Supplement manufacturers are prohibited from
making claims about the ability of their products to diagnose, mitigate,
treat, cure, or prevent a specific disease or class of diseases without
undergoing evaluation as conventional drugs (Dietary Supplement
Health and Education Act, 1994). For herbal products with established
drug interaction liability, the FDA requires mention of potential HDIs
in the prescribing information of victim drugs, but not in the label of
the perpetrator herbal product.
Regulation in the European Union. Herbal product usage varies
widely among countries of the European Union, leading to differences
in regulatory classifications in individual countries. Germany and
France have a long history of herbal product use, reporting combined
sales of $3.2 billion in 2003 (De Smet, 2005). By contrast, Portugal,
Hungary, Ireland, Slovakia, Finland, and Norway have a shorter
history of herbal product use, with less than $0.15 billion in combined
sales in 2003 (De Smet, 2005). Initial attempts in 2002 to harmonize
these disparate views generated safe lists of vitamins and minerals, but
national rules for other nutrients and dietary supplements remained
intact (European Parliament, 2002). With regulation of herbal products
left to the agencies in each member country, at least 27 different
national perspectives exist (Table 1). The second attempt in 2004 to
harmonize perspectives created a category termed traditional herbal
medicinal products (THMPs), providing some progress at the national
level for medicinal products with traditional or historic uses (Silano
et al., 2011). Authorization as a THMP requires that the product be
marketed for at least 30 years, 15 of which must be in an EU member
country (Silano et al., 2011). Registration under this directive requires
more information than the US FDA requires for dietary supplements
but less information than the US FDA or European Medicines Agency
(EMA) requires for conventional drugs. Herbal product manufacturers
were given until April 2011 to register a product for consideration as
a THMP (Silano et al., 2011). Although market harmonization has
begun, decisions as to market authorization are still left to individual
EU member countries. Such incomplete harmonization creates an
environment in which an herbal product can be marketed as a food
supplement in one country, a THMP in a second country, and
prohibited in a third country (Silano et al., 2011).
Regulation in Canada. Herbal products in Canada are regulated by
the Natural Health Product Directorate (NHPD) branch of Health
Canada (Table 1). The role of the NHPD is to “ensure that Canadians
have ready access to natural health products that are safe, effective and
of high quality while respecting freedom of choice and philosophical
and cultural diversity” (Health Canada, 2006). Unlike in the United
States and European Union, herbal product manufacturers in Canada
must provide evidence to support both the safety and efficacy of
TABLE 1
Key regulatory guidance points associated with herbal products
Refer to citations in the text for additional information.
Guidance Points United States European Union Canada
Regulatory authorization DSHEA of 1994 Directive 2002/46/EC, Directive 2004/24/
EC
Natural Health Products Regulations
Regulatory agency US FDA EMA Committee on Herbal Medicinal
Products
Health Canada (NHPD Branch)
Classifications Dietary supplements Traditional plant food supplement or
traditional herbal medicinal product
Natural health product
Safety data required premarketing Yes for ingredients introduced after 1994 Extent of required data dependent on
classification and member country
competent authority
Yes for all products
Adverse event reporting Manufacturers required to inform FDA of
any adverse events reported directly to
the manufacturer
Pharmacovigilance maintained by EMA,
manufacturers, and health care
practitioners
Manufacturers required to monitor
adverse events and report serious
adverse events to Health Canada
Requirement of Good
Manufacturing Practices (GMP)
Modeled after food GMP, required for all
manufacturers in 2010
Required for all products Required for all products
Label requirements Name of each ingredient Exact centesimal product formula Common and proper name of each
medicinal ingredient
Quantity of each ingredient Exact nature of plants/extracts present Quantity of each medicinal ingredient
Contact information for the manufacturer Conditions of use Recommended use, dose, route of
administration, duration of use
The statement “Not evaluated by the
FDA. Not intended to diagnose, treat,
cure, or prevent any disease”
Possible interactions with drugs and/or
foods
Risk information
Lot number and expiry date
Description of source material for each
medicinal ingredient
Permissible health claims Characterize the means by which the
dietary supplement acts to maintain the
normal structure or function in humans
Health claims must be consistent with
recognized physiologic effect and the
degree to which the claimed effect is
demonstrated
Health claims regarding preventing
Schedule A diseases are allowed
provided that they are supported by
sufficient evidence
Not required to be preapproved Evaluated before marketing
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a product before market approval. As part of the required safety
information, a summary report containing information about the in-
teraction potential with other medicinal products, foods, or clinical
laboratory tests must be provided (Health Canada, 2006). Upon
approval, herbal products receive a license and identification number.
All approved herbal products must meet strict labeling requirements.
In addition, the process of removing an herbal product from the market
is less cumbersome than in the United States. Specifically, the
Canadian Health Minister can suspend sales of natural health products
if a manufacturer does not provide requested safety information or if
the Minister has reasonable grounds to believe that the product is
not complying with other provisions of NHPD regulations (Health
Canada, 2006).
HDI Predictions
Current Strategies. Compared with qualitative descriptions of
HDIs, prospective quantitative predictions of these interactions are in
embryonic stages at best. Since herbal products are not regulated in the
same manner as conventional drugs, at least in the United States and
the European Union, rigorous assessment of HDI liability generally is
not requested prior to marketing. As such, HDI studies typically are
initiated upon receipt of case reports documenting a putative inter-
action or data from in vitro experiments highlighting a potential inter-
action. A prospective, systematic process would advance the mechanistic
understanding of HDIs, helping to predict, mitigate, and ideally pre-
vent adverse HDIs.
Limitations of Current Strategies. As aforementioned, herbal
products typically are mixtures of potentially bioactive constituents,
any of which may interact with drug metabolizing enzymes or
transporters. Information from in vitro experiments, preclinical and
clinical studies, and in silico simulations can be used to assess HDI
potential. Static equations usually are not amenable to complex in-
teractions due to multiple constituents; consequently, more sophisti-
cated approaches, such as physiologically based pharmacokinetic
(PBPK) modeling and simulation, are preferable (de Lima Toccafondo
Vieira and Huang, 2012; Huang, 2012). The lack of standardization of
herbal products (discussed earlier), coupled with variable experimental
design across laboratories (Table 2), has produced large variability in
the quality of reported data, rendering application of PBPK modeling,
as well as in vitro to in vivo extrapolation, approaches particularly
challenging. Summarized below are current approaches for evaluating
the drug interaction potential of conventional pharmaceutical com-
pounds that can be applied to herbal products. Milk thistle and res-
veratrol are subsequently presented as case studies.
Evaluation of HDIs in In Vitro Systems. In vitro systems are
fundamental tools used to estimate the contribution of drug
metabolizing enzymes and transporters to the disposition of an herbal
product. Results derived from in vitro experiments can be used to
predict quantitatively the in vivo potential of an HDI. Systems
commonly used to assess metabolism include microsomes, recombi-
nant enzymes, and hepatocytes. Transport activity typically is deter-
mined using cell lines such as Caco-2 or MDCK cells overexpressing
specific human transporters, in which bidirectional transport can be
measured (Cvetkovic et al., 1999; Cui et al., 2001; Troutman and
Thakker, 2003; Kindla et al., 2011; Kimoto et al., 2013; Kock et al.,
2013). Sandwich-cultured hepatocytes, which mimic three-dimensional
hepatic architecture, can be used to estimate biliary transport (Liu et al.,
1999; Annaert et al., 2001). Continual refinement of these systems
provides improved estimates of xenobiotic disposition.
Human-derived microsomes or recombinant enzymes are used to
determine both the potency and mode of enzyme inhibition (Table 2).
Details about the appropriate conduct of these studies are described
elsewhere (Bjornsson et al., 2003; Grimm et al., 2009). Cell lines are
used to determine whether the xenobiotic inhibits transport of probe
substrates such as digoxin [P-glycoprotein (P-gp)] or some statins
[breast cancer resistance protein (BCRP) and organic anion trans-
porting polypeptides (OATPs)]. The likelihood of inhibition occurring
in vivo can be estimated by using the in vitro–determined kinetic
parameters and observed systemic concentrations of the perpetrator
xenobiotic (if available), as discussed subsequently under the section
on modeling and simulation approaches. A caveat is that circulating
concentrations may not represent the HDI liability during first-pass
extraction or may not reflect local concentrations at the site of the
interaction.
Unlike inhibition experiments that can rely on cell fractions, in-
duction experiments must rely on intact cells. Assessment of induction
is dependent upon the measurement of mRNA or protein expression
for both metabolic enzymes and transporters. Increased activity of the
induced protein also must be demonstrated, because increased mRNA
or protein expression may not always correlate with a proportional
increase in activity. The induction response of immortalized cells (e.g.,
Caco-2 or HepG2) may not be as robust as in human hepatocytes be-
cause the immortalization process can alter expression of particular
transcription factors or nuclear receptors.
Evaluation of HDIs in Preclinical Animal Models. Appropriate
animal models are critical in the drug development process. Although
predictions can be made using in vitro data, several key characteristics
of drug/xenobiotic disposition can only be determined in vivo, namely
the relative contribution of metabolic and excretory routes to total
clearance. Moreover, mass balance and the percent contribution of an
enzymatic pathway to overall elimination can only be estimated using
in vivo data. Without these data, the appropriateness of PBPK models
cannot be assessed. Information derived from properly designed PK
studies can be used to develop or refine PBPK models. Thus, in
addition to helping determine bioavailability and tissue localization
of a drug, animal models can provide an estimate of exposure to
metabolites after administration of the parent drug. In general, in vitro
data are scaled to determine drug interaction liability and whether
human in vivo DDI studies are warranted. In some instances, animal
models can provide mechanistic insight into a DDI using an ex-
perimental design that is not amenable to humans. A major dis-
advantage of animal models is differing metabolic and transport pathways
compared with humans, because animals can have enzyme and
transporter orthologs that differ in tissue expression or substrate
specificity (Martignoni et al., 2006; Chu et al., 2013).
Human Clinical Studies. Best practices for appropriate conduct of
human clinical HDI studies closely resemble those for food–drug
interaction studies as reviewed previously (Gurley, 2012; Won et al.,
2012). As with food–drug interaction studies, the critical step in HDI
studies is quantification of the putative perpetrator constituent(s). The
Consolidated Standards of Reporting Trials checklist was updated in
2006 to include herbal medicinal products (Gagnier et al., 2006). The
interventions section of this checklist was extended to highlight the
importance of the name, characteristics, dosage regimen, quantitative
description, and qualitative testing of the herbal product. Although this
checklist is meant to enable quality reporting of trials involving herbal
medicines, the major emphasis of this update is also applicable to
interaction studies. Ideally, with increased awareness, HDI studies will
more closely resemble those for DDIs, guidances for which have been
extensively discussed (European Medicines Agency, 2012; US Food
and Drug Administration, 2012).
Modeling and Simulation Approaches. Modeling and simulation-
based approaches have become useful tools for DDI predictions. The
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TABLE 2




Enzyme Substrate Metric/Outcome Reference
Pooled HLMs Silybin A CYP2C9 (S)-Warfarin Ki, 10 mM Brantley et al. (2010)
Silybin B Ki, 4.8 mM




Testosterone KI, 166 mM
HLMs (two preparations) Silibinin CYP1A2 Caffeine IC50, .200 and .200 mM Beckmann-Knopp et al.
(2000)CYP2A6 Coumarin IC50, .200 and .200 mM
CYP2C9 (S)-Warfarin IC50, 43 and 45 mM
CYP2C19 (S)-Mephenytoin IC50, .200 and .200 mM
CYP2D6 Dextromethorphan IC50, 173 and .200 mM
CYP2E1 Chlorzoxazone IC50, .200 and .200 mM
CYP3A4 Denitronifedipine IC50, 29 and 46 mM
Erythromycin IC50, .200 and .200 mM
HLMs (two preparations) Silibinin CYP2D6 Bufuralol Ki, ND and 8.2 mM Zuber et al. (2002)
CYP2E1 p-Nitrophenol Ki, ND and 28.7 mM
CYP3A4 Nifedipine Ki, 4.9 and 9.0 mM
Pooled HLMs Silibinin CYP1A2 Ethoxyresorufin Ki, 165 mM Jancová et al. (2007)
CYP2C9 Diclofenac Ki, 75 mM
CYP3A4 Testosterone Ki, 21 mM
Pooled HLMs Silymarina CYP2C19 (S)-Mephenytoin Ki, 2.2 mM Doehmer et al. (2008)
CYP2D6 Bufuralol Ki, 11.6 mM
CYP3A4 Testosterone Ki, 12.0 mM
Pooled HLMs Milk thistle
extract
CYP2C8 Paclitaxel Ki, 8.35 mg/ml Doehmer et al. (2011)
CYP2C9 Diclofenac Ki, 9.42 mg/ml
CYP2C19 Mephenytoin Ki, 33.0 mg/ml
CYP2D6 Bufuralol Ki, 68.9 mg/ml





CYP1A2 Acetanilide ,20% ↓ in activity at 10 mM Etheridge et al. (2007)
CYP2C8 Paclitaxel 66% ↓ in activity at 10 mM
CYP2C9 Tolbutamide No inhibition at 1 mMc
CYP2C19 (S)-Mephenytoin ,30% ↓ in activity at 10 mM
CYP2D6 Dextromethorphan ,20% ↓ in activity at 10 mM
CYP2E1 p-Nitrophenol ,20% ↓ in activity at 10 mM
CYP3A4 Midazolam 43% ↓ in activity at 10 mM
Testosterone 43% ↓ in activity at 10 mM
Recombinant enzymes Silibinin UGT1A1 7-Hydroxy-4-(trifluoromethyl)
coumarin
IC50, 1.4 mM Sridar et al. (2004)
UGT1A6 IC50, 28 mM
UGT1A9 IC50, 20 mM
UGT2B7 IC50, 92 mM
UGT2B15 IC50, 75 mM
Pooled HLMs Milk thistle
extract
UGT1A1 Estradiol IC50, 18 mg/ml Mohamed et al. (2010)
Pooled HLMs Milk thistle
extract
UGT1A4 Trifluoperazine ND Mohamed and Frye (2011)
UGT1A6 Serotonin IC50, 59.5 mg/ml





trans-Resveratrol CYP1A1 7-Ethoxyresorufin Ki, 1.2 mM; IC50, 26 mM Chang et al. (2001) and
Mikstacka et al. (2008)CYP1A2 KI, 8.5 mM
KI, 2.4 mM
IC50, .100 mM





trans-Resveratrol CYP1A2 7-Ethoxyresorufin KI, 6 mg/l Piver et al. (2003)
CYP2A6 Coumarin KI, 34 mg/l
CYP2B6 7-Benzoxyresorufin KI, 23 mg/l
CYP2E1 Chlorzoxazone KI, 6 mg/l
CYP3A4 Testosterone KI, 6 mg/l
CYP4A Lauric acid KI, 23 mg/l
Recombinant enzymes trans-Resveratrol CYP1A2 7-Ethoxyresorufin IC50, .50 mM Yu et al. (2003)
CYP2C9 Diclofenac IC50, .50 mM
CYP2C19 (S)-Mephenytoin IC50, 11.6 mM
CYP2D6 Bufuralol IC50, .50 mM
CYP3A4 Testosterone IC50, 1.1 mM
RLMs
Pooled HLMs
trans-Resveratrol ND Paclitaxel IC50, 26.5 mM (6a-hydroxylation)
and 28.5 mM (39-hydroxylation)
Václavíková et al. (2003)
Pooled HLMs trans-Resveratrol UGT1A Estradiol 25% ↓ in 17-glucuronide
formation
at 10 mM; 72% ↓ in 3-
glucuronide
formation at 500 mM
Ung and Nagar (2009)
Recombinant enzyme trans-Resveratrol CYP3A4 Testosterone 59% ↓ in activity at 10 mM Chan and Delucchi (2000)
HLM, human liver microsome; ND, not determined; RLM, rat liver microsome.
aConcentrations reported as silibinin equivalents.
bStandardized to silybin B (21.1% of extract) content.
cActivity not reported at 10 mM.
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first step regarding in vitro to in vivo extrapolation is to recover robust
estimates of requisite kinetic parameters (e.g., Km, Vmax, Ki, KI, kinact).
Single-site Michaelis–Menten kinetics typically are assumed for the
cytochromes P450 (P450); however, the possibility of atypical
kinetics, including enzyme activation, biphasic kinetics, and multien-
zyme kinetics, should be considered, especially if multiple herbal
constituents are involved (Wienkers and Heath, 2005; Tracy, 2006).
Similarly, atypical kinetics such as enzyme activation and partial
substrate inhibition have been reported for conjugative enzymes
(Stone et al., 2003; Uchaipichat et al., 2008; Tyapochkin et al., 2011)
and may complicate recovery of relevant parameters (Iwuchukwu and
Nagar, 2008). Finally, the determination of unbound concentrations in
incubation mixtures to estimate Km (Obach, 1999; Wienkers and
Heath, 2005) is increasingly appreciated. Taken together, selecting the
appropriate kinetic model is imperative for accurate recovery of
parameters that are used as inputs for whole-system models, including
PBPK models.
PBPK models in particular are emphasized in regulatory guidances
for predicting the likelihood and magnitude of DDIs and for providing
greater insight into causes of uncertainty and variability in the
evaluation of DDIs (European Medicines Agency, 2012; US Food and
Drug Administration, 2012). Several commercial software packages
are available that facilitate model development. Differential equation
solving software packages include MATLAB Simulink, Berkeley
Madonna, Wolfram Mathematica, and acsIX; these programs do
not contain predefined model structures or differential equations,
rendering model complexity and flexibility dependent upon the am-
bition and coding acumen of the modeler. Alternatively, software
packages such as Simcyp, PK-Sim, GastroPlus, and MATLAB Sim-
Biology provide template model structures at the expense of full
customization. Regardless of the software package selected, PBPK
models generally require more parameters than other modeling ap-
proaches. Compound-independent physiologic parameters such as
organ weights and blood flows can be obtained from the literature
(Brown et al., 1997; Boecker, 2003). Compound-dependent param-
eters, such as tissue partition coefficients, absorption rate constants,
and metabolic clearances, can be determined from in vitro and animal
experiments or estimated from physicochemical parameters of indi-
vidual constituents (Poulin and Theil, 2000; Rodgers and Rowland,
2007). PBPK models of victim and perpetrator compounds can be
linked through appropriate interaction mechanisms, such as reversible
or time-dependent inhibition, to simulate HDIs (European Medicines
Agency, 2012; US Food and Drug Administration, 2012). Compre-
hensive reviews of PBPK model software packages and applications
are available (Khalil and Laer, 2011; Rowland et al., 2011; Zhao
et al., 2012).
Case Study: Milk Thistle
Product Identification and Usage. Milk thistle [Silybum maria-
num (L.) Gaertn.] is a member of the Asteraceae plant family whose
use in treating hepatic disorders was documented by Pliny the Elder
(AD 23–79) (Kroll et al., 2007; Post-White et al., 2007). More
recently, extracts from the plant have shown promise in preclinical
studies for treatment of hepatic disorders, such as acute hepatitis,
chronic hepatitis B, and hepatitis C (Wei et al., 2013). Evidence of
clinical efficacy, however, is limited (Gordon et al., 2006; Rambaldi
et al., 2007; Seeff et al., 2008; El-Kamary et al., 2009; Payer et al.,
2010; Fried et al., 2012). In addition to treatment of liver disease,
milk thistle extracts may mitigate drug-induced hepatotoxicity from
chemotherapeutic agents used for childhood acute lymphoblastic
leukemia (Ladas et al., 2010) and acute myelogenous leukemia
(McBride et al., 2012). Milk thistle extracts and chemical derivatives
are used in the treatment of fulminant liver failure caused by death cap
mushroom (Amanita phalloides) poisoning (Mengs et al., 2012).
Although milk thistle research remains focused on liver ailments,
recent research has highlighted potential uses for treatment of
obsessive compulsive disorder (Sayyah et al., 2010; Camfield et al.,
2011), type II diabetes (Huseini et al., 2006), b-thalassemia major
(Gharagozloo et al., 2009), influenza A (Song and Choi, 2011), and
prostate cancer chemoprevention (Agarwal et al., 2006; Flaig et al.,
2007; Vidlar et al., 2010). Continuous use of milk thistle products for
nearly 2000 years in treating various ailments suggests putative
efficacy, but again, clinical evidence remains limited.
Extracts from milk thistle are commercially available with varying
degrees of purification and chemical modification. Crude milk thistle
extract often is standardized to contain 65%–80% silymarin and 20%–
35% fatty acids (Kroll et al., 2007). Silymarin is a mixture of at least
seven flavonolignans and the flavonoid taxifolin (Fig. 2). Flavonoli-
gnans are formed by conjugation of taxifolin with coniferyl alcohol to
produce structural isomers with the same molecular weight, enabling
rudimentary calculations of silymarin concentrations in molar units
(Kim et al., 2003a; Davis-Searles et al., 2005; Graf et al., 2007).
Although the abundance of flavonolignans varies among different
preparations, the most prevalent flavonolignans usually are the
diastereoisomer pair silybin A and silybin B (Davis-Searles et al.,
2005; Wen et al., 2008). Silychristin and silidianin also are relatively
abundant in most silymarin preparations. The diastereoisomeric pair
isosilybin A and isosilybin B, as well as isosilychristin, are relatively
scarce in most preparations. Semipurification of the crude extract
yields a roughly 1:1 mixture of silybin A and silybin B, termed
silibinin. The semipurified mixture of isosilybin A and isosilybin B,
isosilibinin, has been used in preclinical research but is not yet
available as a commercial preparation (Kroll et al., 2007). Chemical
modification of silybin A and silybin B to increase water solubility for
administration as an intravenous formulation led to generation of the
dihemisuccinate ester derivative, Legalon SIL (Mengs et al., 2012). As
aforementioned about herbal products in general, large differences
exist in the relative composition of the various constituents in milk
thistle products (with the exception of prescription preparations
available in some countries) (Davis-Searles et al., 2005; Lee et al.,
2006; Wen et al., 2008).
Metabolism of Milk Thistle Constituents. Investigations of the
metabolic clearance of milk thistle products have focused on the
oxidative and conjugative metabolism of silibinin. The major oxidative
metabolite of silibinin is an O-demethylated product generated by
CYP2C8 in human liver microsomes (Gunaratna and Zhang, 2003;
Jancová et al., 2007). All milk thistle flavonolignans share the methoxy
moiety (Fig. 2), located in a region of the coniferyl alcohol that does not
participate in the conjugation to taxifolin. Thus, oxidation of this moiety
could be similar among all flavonolignans. Relative to the O-demethyl
product of silibinin, formation of the monomethylated and dimethylated
products was below the limit of quantification (Gunaratna and Zhang,
2003). Milk thistle flavonolignans are conjugated extensively by uridine
59-diphospho-glucuronosyltransferases (UGTs). Conjugation of silybin A
and silybin B by human liver microsomes and hepatocytes showed
preferential formation of the 7-O-glucuronide (Jancová et al., 2011). Among
recombinant UGTs, UGT1A1, UGT1A3, UGT1A8, and UGT1A10 con-
tributed to silybin A and silybin B conjugation (Jancová et al., 2011).
Human Pharmacokinetics of Milk Thistle Constituents. After
oral administration, milk thistle flavonolignans are absorbed rapidly,
with maximum systemic concentrations achieved within less than
2 hours (Weyhenmeyer et al., 1992; Kim et al., 2003b; Wen et al.,
2008). As with many natural products based on a flavonoid scaffold,
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milk thistle flavonolignan oral availability is low due to extensive
presystemic conjugation by UGTs and sulfotransferases (SULTs)
(Wen et al., 2008). Upon reaching the systemic circulation, parent
flavonolignan clearance is rapid, with a terminal elimination half-life
of less than 4 hours (Kim et al., 2003a,b; Wen et al., 2008; Zhu et al.,
2013). Systemic exposure to conjugated flavonolignans is consistently
higher than to parent flavonolignans. For example, exposure to conju-
gated silybin B, as measured by the area under the concentration-time
curve (AUC), was nearly 9-fold higher than that of the unconjugated
parent (converted to molar units) in healthy volunteers after a 600-mg
dose of milk thistle (Wen et al., 2008). Subsequent to conjugation,
flavonolignans are transported into the bile (Schandalik et al., 1992),
and deconjugation in the intestine permits reabsorption and enter-
ohepatic recirculation of flavonolignans. Renal clearance of total
(unconjugated plus conjugated) silybin A and silybin B is roughly
30 ml/min, with approximately 5% of the dose eliminated in the urine
Fig. 2. Structures of known milk thistle constituents.
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as conjugates (Weyhenmeyer et al., 1992). Compared with healthy
volunteers, patients with hepatitis C and patients with nonalcoholic
fatty liver disease demonstrated increased exposure to milk thistle
flavonolignans and conjugated flavonolignans (Schrieber et al., 2008).
Patients with extrahepatic biliary obstruction showed increased sys-
temic exposure to total, but not parent, silibinin. This observation
suggests that biliary excretion is rate-limiting for the clearance of
conjugated metabolites but not the parent flavonolignans (Schandalik
and Perucca, 1994).
Inhibition of Drug Metabolizing Enzymes in Recombinant
Enzymes and Microsomes. The inhibitory effects of milk thistle
extracts and constituents depend on the preparation as well as the
enzyme system and substrate tested. Silibinin has been shown to be
a mechanism-based inhibitor of CYP2C9 and CYP3A4 in recon-
stituted or recombinant enzymes (Sridar et al., 2004; Brantley et al.,
2013) or a reversible inhibitor of CYP2C9 (Jancová et al., 2007;
Brantley et al., 2010) and CYP3A4 (Zuber et al., 2002; Jancová et al.,
2007) in human liver microsomes (Table 2). Based on IC50 and the
caveat that the relationship to Ki is not always clear (i.e., depends on
substrate concentration relative to Km and mechanism of inhibition),
the inhibitory potency of silibinin toward CYP3A4 may be substrate
dependent, with a higher potency toward oxidation of nifedipine
(Beckmann-Knopp et al., 2000; Zuber et al., 2002) and testosterone
(Jancová et al., 2007) than erythromycin (Beckmann-Knopp et al.,
2000). Although silibinin constitutes nearly 50% of silymarin,
silymarin extract appears to be a more potent inhibitor of
CYP2C19-mediated (S)-mephenytoin 49-hydroxylation than silibinin
(Ki = 2.2 mM versus IC50 .200 mM) (Beckmann-Knopp et al., 2000).
Compared with the P450s, inhibition of UGT activity by milk thistle
constituents is less studied. Silibinin inhibited recombinant UGT1A1-
mediated 7-hydroxy-4-trifluoromethylcoumarin metabolism with an
IC50 of 1.4 mM (Sridar et al., 2004), whereas a milk thistle extract
inhibited UGT1A-mediated estradiol metabolism in human liver
microsomes with an IC50 of nearly 40 mM (Mohamed et al., 2010).
Modulation of Drug Metabolizing Enzymes and Transporters
in Cell Systems. As with recombinant enzymes and microsomes, the
effects of milk thistle extracts on enzyme/transporter expression and
activity in intact cell systems differs depending on the extract, cell
system, and probe substrate tested. Silymarin was shown to decrease
CYP3A4-mediated testosterone metabolism by 50% relative to vehicle
control in plated human hepatocytes (Venkataramanan et al., 2000).
Silibinin had no effect on cortisol metabolism in Caco-2 cells modified
to express CYP3A4 (Patel et al., 2004) (Table 3). The effect of milk
thistle on P-gp was more variable than on drug metabolizing enzymes.
Silibinin decreased P-gp expression by nearly 70% in Caco-2 cells
(Budzinski et al., 2007) but had no effect on ritonavir transport in
either Caco-2 or MDCK-MDR1 cells (Patel et al., 2004). In contrast,
silymarin inhibited the P-gp–mediated transport of digoxin and
vinblastine in Caco-2 cells (Zhang and Morris, 2003a) and of
daunomycin in MDA435/LCC6 cells (Zhang and Morris, 2003b). In
addition to inhibiting efflux transporters, silymarin was shown to
inhibit the uptake of estradiol-17b-glucuronide and estrone-3-sulfate
mediated by OATP1B1, OATP1B3, and OATP2B1 in transfected
Xenopus oocytes and HEK cells (Deng et al., 2008; Kock et al., 2013).
Milk Thistle–Drug Interaction Predictions. To the authors’
knowledge, no studies to date have investigated the drug interac-
tion liability of milk thistle using PBPK modeling and simulation.
Of the reported in vitro studies that mention HDIs with milk
thistle products, the majority urge caution when such products are
coadministered with sensitive victim drugs due to unknown interaction
liability (Beckmann-Knopp et al., 2000; Venkataramanan et al., 2000;
Nguyen et al., 2003; Sridar et al., 2004; Etheridge et al., 2007; Deng
et al., 2008; Brantley et al., 2010; Mohamed et al., 2010; Doehmer
et al., 2011; Mohamed and Frye, 2011). Other studies (Zuber et al.,
2002; Jancová et al., 2007; Doehmer et al., 2008) dismiss interaction
liability due to the low plasma concentrations of milk thistle con-
stituents or low inhibitory potency. Regardless of interpretation, ac-
curate predictions of milk thistle–drug interaction liability remain
elusive.
Preclinical Milk Thistle–Drug Interaction Studies. Silymarin
increased risperidone AUC and maximal plasma concentration (Cmax)
in rats after repeated oral doses, consistent with inhibition of P-gp (Lee
et al., 2013) (Table 4). Silibinin also increased tamoxifen AUC in rats
in a dose-dependent manner (Kim et al., 2010). Unlike for humans,
tamoxifen disposition in the rat has not been defined. Although the
mechanism for this increased exposure could not be identified, the net
effect could reflect inhibition of one or more rodent orthologs of the
relevant human enzymes and transporters.
Clinical Milk Thistle–Drug Interaction Studies. The clinical
interaction liability of milk thistle products has been examined over
the past decade (Table 5). Apart from increased exposure to losartan
and talinolol (Han et al., 2009b), the majority of studies reported no
clinically significant interactions. Limitations in study design and lack
of information about the composition of the milk thistle preparations
may have hampered detection of a significant interaction.
Relatively low dosages of silymarin (140 mg three times a day)
inhibited the hepatic clearance of the CYP2C9/3A substrate losartan in
Chinese subjects homozygous for the CYP2C9 reference allele
(CYP2C9*1), leading to a doubling of losartan AUC (Han et al.,
2009b). Individuals carrying a reduced activity allele (CYP2C9*3)
experienced an increase in losartan Cmax without a significant increase
in AUC (Han et al., 2009b). Losartan is a prodrug that is converted to
the active metabolite, E-3174, by CYP2C9. Consistent with a decrease
in formation clearance by CYP2C9, exposure to E-3174 was de-
creased after milk thistle administration. The decrease was relatively
modest (approximately 15%), indicating limited clinical importance of
this interaction (Han et al., 2009b). However, clinically important
interactions with larger doses of milk thistle or more sensitive victim
drugs known to be affected by CYP2C9 inhibition (e.g., warfarin,
phenytoin, celecoxib) cannot be dismissed.
Studies of interactions between milk thistle and the HIV protease
inhibitors and CYP3A substrates indinavir and ritonavir demonstrated
no interaction. Long-term administration of milk thistle products (2–4
weeks) at various dosages (160–450 mg three times a day) did not
alter indinavir Cmax or AUC significantly (Piscitelli et al., 2002;
DiCenzo et al., 2003; Mills et al., 2005). Plasma Cmax and AUC of
indinavir decreased after milk thistle administration (by 8.8% and
9.2%, respectively), which is inconsistent with inhibition of CYP3A
(Piscitelli et al., 2002). Interaction studies with indinavir are not
amenable to fixed sequence design because indinavir alone exhibits
significantly decreased systemic exposure after long-term treatment,
consistent with autoinduction of CYP3A. Compared with baseline
conditions, healthy volunteers had 40% lower indinavir exposures 1 week
after a 28-day cycle of indinavir (Mills et al., 2005). Indinavir is also
a potent CYP3A inhibitor after acute (single dose) treatment,
decreasing study sensitivity to detect mild or moderate inhibition of
CYP3A. As with indinavir, milk thistle administration with ritonavir
or darunavir was not associated with a significant change in drug
exposure in HIV-infected patients (Moltó et al., 2012). Like
indinavir, ritonavir is a potent CYP3A inhibitor after acute treatment,
decreasing sensitivity to detect further enzyme inhibition. Based on
the complex modulation of CYP3A by these victim drugs, these
results cannot be extrapolated to milk thistle interactions with other
CYP3A substrates, warranting further evaluation.
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TABLE 3








Human hepatocytes Silymarin CYP3A4 Testosterone 48 h at 100 mM 50% ↓ in activity Venkataramanan et al.
(2000)UGT1A6/9 4-Methylumbelliferone 65% ↓
in activity




Kosina et al. (2005)
CYP3A4
Human hepatocytes Silymarin CYP2C9 Diclofenac 72 h at 100 mM No change in
activity







CYP1A2 7-Ethoxyresorufin 72 h at 50 mg/ml 1.1- to 8.5-fold ↑
in activity
Doehmer et al. (2011)
CYP2B6 (S)-Mephenytoin 0.3- to 2.7-fold ↑
in activity
CYP2C9 Diclofenac 0.7- to 1.6-fold ↑
in activity
CYP2E1 Chlorzoxazone 2.0- to 3.0-fold ↑
in activity
CYP3A4 Testosterone 0.4- to 1.3-fold ↑
in activity
Caco-2 cells Silibinin CYP3A4 NA 48 h at 10 mM 9% ↓ in protein Budzinski et al. (2007)
P-gp 69% ↑ in protein




Vinblastine 80% ↑ in
accumulation
Caco-2 cells Silibinin CYP3A4 Cortisol 30 min No change Patel et al. (2004)








Panc-1 cells Silymarin MRP1 Daunomycin 2 h at 100 mM 3.1-fold ↑ in
accumulation
Nguyen et al. (2003)






BCRP Methotrexate 2 min at 1000 mg/ml 45% ↓ in transport Tamaki et al. (2010)
MCF-7 MX100
cells




EC50, 34 mM Zhang et al. (2004)
BCRP-transfected
MDCK cells
Silymarin BCRP Rosuvastatin 1 h Ki, 98 mM Deng et al. (2008)
OATP1B1-transfected
Xenopus oocytes
OATP1B1 30 min Ki, 0.93 mM
HEK293-OATP1B1 Silymarin OATP1B1 Estradiol-17-
b-glucuronide
3 min IC50, 1.3 mM Kock et al. (2013)
HEK293-OATP1B3 OATP1B3 IC50, 2.2 mM
MDCKII-OATP2B1 OATP2B1 Estrone-3-sulfate IC50, 0.3 mM
HepG2, MCF-7 trans-
Resveratrol





























Berge et al. (2004)
Caco-2 cells trans-
Resveratrol
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Case Study: Resveratrol
Product Identification and Usage. Resveratrol (3,5,49-trihydroxy-
trans-stilbene) (Fig. 3) is a naturally occurring phytoalexin produced
by a variety of plants, including grapes, mulberries, and peanuts
(Wang et al., 2002). Resveratrol has demonstrated antioxidant
(Leonard et al., 2003), lipid-lowering (Miura et al., 2003), chemo-
preventive (Kundu and Surh, 2008), and cardioprotective properties
(Kopp, 1998). Clinical evidence regarding the cardioprotective and
cancer chemopreventive effects is limited (Walle et al., 2004;
Aggarwal and Shishodia, 2006). Current clinical trials with resveratrol
include evaluation of effects on type II diabetes, colon cancer,
Alzheimer’s disease, Friedreich’s ataxia, obesity, nonalcoholic fatty
liver disease, and polycystic ovary syndrome (http://clinicaltrials.gov/
ct2/results?term=resveratrol).
Metabolism of Resveratrol. Resveratrol contains three phenolic
moieties (Fig. 3) that are vulnerable to conjugation by UGTs and
SULTs (De Santi et al., 2000a,b; Walle et al., 2004). As with milk
thistle flavonolignans, resveratrol undergoes rapid conjugation in the
intestine and liver (Wenzel et al., 2005), limiting oral bioavailability
(De Santi et al., 2000a,b). Both the cis- and trans-isomers are converted to
resveratrol-3-O-glucuronide and resveratrol-49-O-glucuronide in human
liver microsomes and recombinant UGTs (Aumont et al., 2001). The cis-
isomer is glucuronidated more rapidly than the trans-isomer, sug-
gesting regioselective and stereoselective glucuronidation of resver-
atrol. Resveratrol-3-O-sulfate is the most abundant SULT-mediated
metabolite (Yu et al., 2003; Boocock et al., 2007). Other metabolites
include trans-resveratrol-49-sulfate, trans-resveratrol-3,5-disulfate, trans-
resveratrol-3,49-disulfate, and trans-resveratrol-3,49,5-trisulfate. The
lack of authentic standards of some of these metabolites, coupled
with the prohibitive cost of some commercially available metabo-
lites, has precluded quantitation in biologic matrices (Wenzel et al.,
2005). Nevertheless, several laboratories have published synthetic
methods for resveratrol conjugates (Wang et al., 2004; Iwuchukwu
et al., 2012).
Human Pharmacokinetics of Resveratrol. After oral administra-
tion of resveratrol (0.36 mg/kg body weight or approximately 25 mg/
70 kg) dissolved in white grape juice, white wine, or vegetable
homogenate (V8 juice) to healthy volunteers, peak concentrations
TABLE 4









Silibinin 0.5 mg/kg p.o. Rats (6/arm) Tamoxifen 10 mg/kg p.o Cyp3a Cyp2d
P-gp
1.2-fold ↑ in Cmax 1.2-fold ↑ in
AUC
Kim et al. (2010)
Silibinin 2.5 mg/kg p.o. 1.5-fold ↑ in Cmax 1.4-fold ↑ in
AUC
Silibinin 10 mg/kg p.o. 1.8-fold ↑ in Cmax 1.7-fold ↑ in
AUC
Silibinin 175 mg/kg p.o.
7 d prior to test substrate
Male Sprague-
Dawley
Rats (6 per arm)
Trazodone 5 mg/kg i.v.c Cyp3a 12% ↓ in Cmax Chang et al. (2009)
No change in AUC
Silibinin 350 mg/kg p.o.
7 d prior to test substrate
30% ↓ in Cmax 8% ↓ in AUC
Silymarin 500 mg/kg p.o.
7 d prior to test substrate
No change in Cmax
20% ↓ in AUC
Silymarin 1000 mg/kg p.o.
7 d prior to test substrate
No change in Cmax
43% ↓ in AUC
Silymarin 1000 mg/kg p.o.
4 h prior to test substrate
238% ↑ in Cmax 3% ↑ in AUC





Rats (5 per arm)
Risperidone
6 mg/kg p.o.
P-gp 1.3-fold ↑ in Cmax Lee et al. (2013)
No change in AUC
Silymarin 40 mg/kg p.o.
5 d prior to test substrate
2.4-fold ↑ in Cmax 1.7-fold ↑ in
AUC
Silibinin 30 mg/kg i.v. Rats (6 per arm) Pyrazinamide 50 mg/kg i.v. Xanthine oxidase 21% ↑ in Cmax Wu and Tsai
(2007)5% ↑ in AUC
Pyrazinoic acid
30 mg/kg i.v.
320% ↑ in Cmax
420% ↑ in AUC
Silibinin 100 mg/kg p.o for 4 d Pyrazinamide
50 mg/kg i.v.
22% ↑ in Cmax
6% ↓ in AUC
Pyrazinoic acid
30 mg/kg i.v.
260% ↑ in Cmax
350% ↑ in AUC
Resveratrol 0.3 or 1 g/kg
per day p.o. for 28 d
Male and female
CD
rats (5 per arm)
NA Cyp, Ugt, Gst,
Nqo-1
↑ in Gst, Nqo-1, and Ugt1a1,
Ugt1a6,
and Ugt1a7 mRNA in liver
Hebbar et al.
(2005)
Resveratrol 0.5–10 mg/kg intragastric Male Sprague-
Dawley
rats (6 per arm)
Diltiazem 5 mg/kg
i.v. or 15 mg/kg p.o.
Cyp3a, P-gp 20%–60% ↑ in bioavailability Hong et al. (2008)
Resveratrol 10 mg/kg i.p. Male Swiss albino
mice
(3 to 4 per arm)
Pyrogallol 40 mg/kg i.p. for
1–4 wk
Cyp, Gst ↓ in Cyp1a2 and Cyp2e1
activity,




i.p. once daily for 1 or 7 d
Male Swiss albino
CD1
mice (8 per arm)
NA Cyp, Ugt, Gst Up to 67% ↓ in hepatic and up
to 97% ↓ in lung Cyp activity
Canistro et al.
(2009)
83% ↑ in hepatic Ugt activity
83% ↓ in lung Ugt activity
22% ↓ in hepatic Gst activity
76% ↓ in lung Gst activity
NA, not applicable.
aHuman ortholog responsible for metabolism or transport of test substrate.
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Milk thistle 175 mg
b.i.d. for 4 wk
12 healthy volunteers (6 women) Caffeine 100 mg CYP1A2 4.8% ↓ in phenotypic ratio Gurley et al.
(2004)
Debrisoquine 5 mg CYP2D6 1.0% ↓ in phenotypic ratio
Chlorzoxazone 250 mg CYP2E1 1.1% ↑ in phenotypic ratio
Midazolam 8 mg CYP3A4 7.8% ↓ in phenotypic ratio
Milk thistle 175 mg
t.i.d. for 2 wk
6 healthy Chinese men
(CYP2C9*1/*1)
Losartan 50 mg CYP2C9 90% ↑ in Cmax Han et al.
(2009b)
110% ↑ in AUC
6 healthy Chinese men
(CYP2C9*1/*3)
41% ↑ in Cmax
1.0% ↑ in AUC
Milk thistle 300 mg
t.i.d. for 2 wk
16 healthy volunteers (8 women) Debrisoquine 5 mg CYP2D6 3.2% ↓ in urinary recovery ratio Gurley et al.
(2008)
Milk thistle 200 mg
t.i.d. for 4 d
6 cancer patients (4 women) Irinotecan 125 mg/m2 CYP3A4 and
UGT1A1
7.7% ↑ in Cmax van Erp et al.
(2005)
16% ↑ in AUC
Milk thistle 200 mg
t.i.d. for 12 d
90-min i.v. infusion 3.2% ↑ in Cmax
14% ↑ in AUC
Milk thistle 175 mg
t.i.d. for 3 wk
10 healthy volunteers (4 women) Indinavir 800 mg, 4
doses 8 h apart
CYP3A4 9.2% ↓ in Cmax Piscitelli et al.
(2002)
8.8% ↓ in AUC
Milk thistle 160 mg
t.i.d. for 2 wk
10 healthy volunteers (3 women) Indinavir 800 mg, 4
doses 8 h apart
CYP3A4 11% ↓ in Cmax DiCenzo et al.
(2003)
6.3% ↓ in AUC
Milk thistle 450 mg
t.i.d. for 30 d
16 healthy male volunteers Indinavir 800 mg, 3
doses 8 h apart
CYP3A4 4.9% ↓ in Cmax Mills et al.
(2005)
4.4% ↓ in AUC
Milk thistle 150 mg
t.i.d. for 2 wk
15 male HIV patients (4
coinfected with HCV)
Darunavir 600 mg CYP3A4 17% ↓ in Cmax Moltó et al.
(2012)
14% ↓ in AUC
Ritonavir 100 mg 10% ↓ in Cmax
11% ↓ in AUC
Milk thistle extract 300
mg
t.i.d. for 14 d
19 healthy volunteers (9 women) Midazolam 8 mg CYP3A4 6.5% ↑ in Cmax Gurley et al.
(2006a)
2.8% ↑ in AUC
Milk thistle 280 mg 10
and 1.5 h before
nifedipine
16 healthy male volunteers Nifedipine 10 mg CYP3A4 30% ↓ in Cmax Fuhr et al.
(2007)
13% ↑ in AUC
Silymarin140 mg
t.i.d. for 14 d
12 healthy male volunteers Ranitidine
150 mg
P-gp 7.6% ↑ in Cmax
4.2% ↓ in AUC
Rao et al.
(2007)
Silymarin 140 mg t.i.d.
for 3 d before and
2 d after rosuvastatin
8 healthy Korean men Rosuvastatin 10 mg
1 h after AM silymarin
OATP1B1
and BCRP
7.5% ↓ in Cmax Deng et al.
(2008)
6.5% ↓ in AUC
Milk thistle 175 mg
t.i.d. for 2 wk
6 healthy Chinese men (MDR1
3435CC)
Talinolol 100 mg P-gp 43% ↑ in Cmax Han et al.,
2009a
22% ↑ in AUC
6 healthy Chinese men (MDR1
3435CT)
40% ↑ in Cmax
37% ↑ in AUC
6 healthy Chinese men (MDR1
3435TT)
1% ↑ in Cmax
21% ↑ in AUC
Milk thistle 300 mg
t.i.d. for 14 d
16 healthy volunteers (8 women) Digoxin 0.4 mg P-gp 13% ↓ in Cmax Gurley et al.
(2006b)
9.4% ↓ in AUC
Resveratrol 1 g once
daily for 4 wk
42 healthy volunteers (31
women)




Losartan 25 mg CYP2C9 173% ↑ in losartan/E3174
0–8 h urine molar ratio
Dextromethorphan
30 mg
CYP2D6 70% ↑ in dextromethorphan/ dextrorphan
0–8 h urine molar ratio
Buspirone 10 mg CYP3A4 33% ↑ in AUC
NA GST-p ↔ in GST-p activity (1-chloro-2,4-
dinitrobenzene glutathionylation
in lymphocytes)
NA UGT1A1 ↔ in UGT1A1 activity (bilirubin
conjugation)
HCV, hepatitis C virus; NA, not applicable.
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(approximately 2 mM) were detected within 30 minutes (Goldberg
et al., 2003). 14C-Resveratrol (25 mg) was administered intravenously
and orally to healthy volunteers to examine the absorption, metab-
olism, and oral bioavailability of resveratrol; similar peak concen-
trations were observed within 1 hour after oral administration (Walle
et al., 2004). Resveratrol underwent rapid presystemic metabolism,
possibly contributing to the low bioavailability (,5%). A second
resveratrol peak was observed at 4–8 hours, which was attributed to
enterohepatic recirculation of the conjugated metabolites (Marier
et al., 2002; Walle et al., 2004). Maximum resveratrol concentrations
after grape juice, white wine, or 14C-resveratrol administration were
well below the EC50 values (5–100 mM) determined for various
pharmacologic effects. Likewise, resveratrol doses from dietary
exposure are low, leading to systemic concentrations well below
pharmacologically relevant concentrations; as such, substantial sup-
plementation may be required to attain a biologic effect (Goldberg
et al., 2003).
Because resveratrol is metabolized extensively in vivo, the me-
tabolites have been hypothesized to provide an inactive pool of
resveratrol and extend pharmacologic activity beyond the short half-
life of the parent compound (Walle et al., 2004; Wang et al., 2004;
Wenzel et al., 2005). Resveratrol metabolites have also been
hypothesized to have pharmacologic activity (Calamini et al., 2010;
Hoshino et al., 2010), showing cyclooxygenase inhibition, nuclear
factor-kB inhibition, and antiestrogenic effects (Aires et al., 2013;
Ruotolo et al., 2013). Further studies are needed to test these
hypotheses as well as to determine the extent of conversion of
metabolites back to the parent compound (Goldberg et al., 2003;
Walle et al., 2004; Wang et al., 2004).
Inhibition of Drug Metabolizing Enzymes by Resveratrol. The
inhibitory effects of resveratrol are enzyme system dependent
(Table 2). Resveratrol was reported to inhibit the P450-mediated
metabolism of 7-ethoxyresorufin in human liver microsomes and
recombinant enzymes and was shown to be a mechanism-based in-
hibitor of CYP1A2 but a reversible, mixed-type inhibitor of CYP1A1
and CYP1B1 (Chang et al., 2001). Resveratrol suppressed CYP1A1
expression in HepG2 cells by preventing aryl hydrocarbon receptor
activation and xenobiotic response element binding; these activities
were hypothesized to contribute to the chemopreventive effect of
resveratrol (Ciolino et al., 1998). Resveratrol was shown to be
a mechanism-based inhibitor of recombinant CYP3A4 (Chan and
Delucchi, 2000). High resveratrol concentrations (10–500 mM) in-
hibited estradiol glucuronidation in human liver microsomes (Ung and
Nagar, 2009). Resveratrol inhibited SULT1E1 activity in primary
human mammary epithelial cells, as measured by the formation of
17b-estradiol-3-sulfate (Otake et al., 2000).
Induction of Drug Metabolizing Enzymes by Resveratrol.
Resveratrol showed transcriptional induction of UGT1A1 in Caco-2
cells (Iwuchukwu et al., 2011). UGT1A1 mRNA increased by 3- to 5-
fold and was hypothesized to occur via activation of the aryl
hydrocarbon receptor and nuclear factor erythroid 2–related factor
(Nrf-2) by resveratrol. A combination of resveratrol and another
polyphenol, curcumin, had a synergistic effect on UGT1A1 induction,
whereas a combination of resveratrol and chrysin, also a polyphenol,
had an additive effect on UGT1A1 induction in Caco-2 cells
(Iwuchukwu et al., 2011). In HepG2 cells treated with 10 or 30 mM
resveratrol, mRNA and protein content of UGT1A1 and UGT2B7
increased after 24 and 48 hours (Lançon et al., 2007). Induction was
observed in vivo in rats treated with 0.3, 1, or 3 mg/kg per day of
resveratrol for 28 days. Hepatic gene expression of rat Ugt 1a1, 1a6,
and 1a7 was upregulated with increasing doses of resveratrol. This
increase in expression was accompanied by an increase in Ugt activity
in liver microsomes prepared from these animals (Hebbar et al., 2005).
Modulation of Transporters by Resveratrol. Resveratrol and
associated monoconjugates are substrates for several transporters,
including BCRP, MRP (multidrug resistance-associated protein) 2,
and MRP3 (Alfaras et al., 2010; Planas et al., 2012; van de Wetering
et al., 2009). Modulation of transporter activity by resveratrol has been
examined using various cell lines. Resveratrol alone did not alter MDR1
expression in MCF-7 and HeLa cells, but resveratrol in combination
with docetaxel or with doxorubicin reduced MDR1 expression in HeLa
cells (Al-Abd et al., 2011). Resveratrol also reduced P-gp activity and
significantly increased the intracellular accumulation of doxorubicin
(Al-Abd et al., 2011). Resveratrol, as well as other dietary components,
have been shown to modulate BCRP (Ebert et al., 2007; You and
Morris, 2007). Although 50 mM resveratrol induced MRP2 activity in
HepG2-C3 cells, this same concentration inhibited genistein-mediated
MRP2 mRNA induction (Kim et al., 2011b). Resveratrol metabolites
were reportedly weak competitive inhibitors of MRP3-mediated trans-
port of estradiol 17-b-glucuronide (van de Wetering et al., 2009).
Few in vivo studies have assessed the effect of resveratrol on
transporter activity. Biliary excretion of the Mrp2 substrate,
bromosulphothalein, was inhibited competitively by resveratrol or
associated glucuronide in Wistar rats (Maier-Salamon et al., 2008).
Interactions between various transporters and resveratrol and other
nutrients inherently are complex, as detailed in comprehensive reviews
(You and Morris, 2007; Li et al., 2012).
PK Modeling of Resveratrol. Various PK modeling approaches
have been used to characterize the disposition of resveratrol and
metabolites. For example, population PK modeling was used to
describe resveratrol disposition (Colom et al., 2011). Traditional
compartmental modeling was used to distinguish the metabolite
kinetics of preformed from generated metabolites (Sharan et al., 2012).
Independent models for resveratrol (three-compartment model) and
two major metabolites, resveratrol-3-glucuronide (enterohepatic recir-
culation model) and resveratrol-3-sulfate (2-compartment model), were
incorporated. The pharmacokinetics of structurally similar dietary
Fig. 3. Structures of resveratrol and major conjugated metabolites.
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flavonoids alone or in combination with coadministered drugs have
been characterized using various methods (Moon and Morris, 2007;
Wang and Morris, 2007; Lin et al., 2008; Li and Choi, 2009).
Collectively, these approaches provide a framework for developing
tools to predict resveratrol–drug interactions.
Clinical HDI Studies of Resveratrol. The potential for resveratrol
to modulate drug metabolizing enzyme activity was examined in
healthy subjects (Chow et al., 2010). Resveratrol had no effect on
UGT1A1 or glutathione S-transferase activity, but in general, P450
activity was inhibited (Table 5). Comprehensive reviews of ongoing
clinical trials involving resveratrol have been published (Patel et al.,
2011; Smoliga et al., 2011). Additional human data regarding drug
interaction liability are forthcoming.
Summary
Herbal product usage likely will continue to increase, in part due to
attempts by consumers to decrease medical costs through self-diagnosis
and treatment. In parallel, the prevalence of concomitant administration
of herbal products with conventional medications will increase. Despite
the mounting likelihood of HDIs, a standard system for evaluating the
drug interaction liability of herbal products remains elusive. The high
compositional variability inherent to herbal products, multiple perpe-
trator constituents, scant knowledge of perpetrator constituent pharma-
cokinetics, and differing regulatory perspectives render prospective
assessment of HDIs more challenging than DDIs. Taken together, an
unprecedented opportunity exists to develop a framework for improving
HDI predictions. Strategies to evaluate conventional DDIs, such as
integrating in vitro parameters with the pharmacokinetics of individual
herbal product constituents into PBPK interaction models, could be
applied to herbal products, helping prioritize them for clinical evaluation.
Adoption of these strategies should streamline safety assessment of herbal
products, assist in the management of HDIs, and ultimately promote the
safe use of herbal products.
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